Cilostazol
- Generic Name
- Cilostazol
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C20H27N5O2
- CAS Number
- 73963-72-1
- Unique Ingredient Identifier
- N7Z035406B
- Background
Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both primary and secondary aggregation and reducing calcium-induced contractions.
- Indication
Indicated for the alleviation of symptoms of intermittent claudication (pain in the legs that occurs with walking and disappears with rest).
- Associated Conditions
- Intermittent Claudication
- Associated Therapies
- -
PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
- Conditions
- Brain IschemiaIntracranial Hemorrhages
- Interventions
- Drug: CilostazolDrug: ProbucolDrug: AspirinDrug: placebo of aspirinDrug: placebo of cilostazolDevice: ankle-brachial index (ABI)Device: intima-medial thickness (IMT)Device: new asymptomatic brain hemorrhageDevice: new ischemic lesions on follow-up FLAIR images
- First Posted Date
- 2009-11-13
- Last Posted Date
- 2015-12-24
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 1600
- Registration Number
- NCT01013532
- Locations
- 🇰🇷
Korea University Ansan Hospital, Ansan, Gyeonggi-do, Korea, Republic of
🇰🇷Hanyang University Medical Center, Seoul, Korea, Republic of
🇰🇷Wonju Christian Hospital, Wonju, Gangwon-do, Korea, Republic of
Efficacy Study of Cilostazol Loading in Elective Percutaneous Coronary Intervention
- Conditions
- Angioplasty, Transluminal, Percutaneous Coronary
- Interventions
- Drug: CilostazolDrug: Placebo
- First Posted Date
- 2009-07-14
- Last Posted Date
- 2009-07-21
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 400
- Registration Number
- NCT00938522
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Adjunctive Cilostazol Versus High Maintenance-dose ClopidogrEL in Acute Myocardial Infarction (AMI) Patients According to CYP2C19 Polymorphism
- Conditions
- Myocardial Infarction
- Interventions
- First Posted Date
- 2009-06-08
- Last Posted Date
- 2009-11-10
- Lead Sponsor
- Gyeongsang National University Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT00915733
- Locations
- 🇰🇷
Gyeongsang National University Hospital, Jinju, Korea, Republic of
Sufficient Treatment of Peripheral Intervention by Cilostazol
- First Posted Date
- 2009-06-03
- Last Posted Date
- 2010-07-22
- Lead Sponsor
- Kansai Rosai Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT00912756
- Locations
- 🇯🇵
Omihachiman Community Medical Center, Omihachiman city, Shiga, Japan
🇯🇵Department of Cardiology,Naganoken Koseiren Shinonoi, Nagano-city, Nagano, Japan
🇯🇵Kokura Memorial Hospital, Kitakyusy, Japan
Comparison of Platelet Inhibition With Adjunctive Cilostazol Versus High Maintenance-Dose Clopidogrel According to Hepatic Cytochrome 2C19 Allele (CYP2C19) Polymorphism
- Conditions
- Coronary Artery StenosisMaximal Platelet AggregationLate Platelet AggregationHigh Post-Treatment Platelet Reactivity
- Interventions
- First Posted Date
- 2009-05-01
- Last Posted Date
- 2009-05-01
- Lead Sponsor
- Gyeongsang National University Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT00891670
- Locations
- 🇰🇷
Gyeong-Sang National University Hospital, Jinju, Gyeong-Nam, Korea, Republic of
Cilostazol Versus Aspirin for Primary Prevention of Atherosclerotic Events
- First Posted Date
- 2009-04-23
- Last Posted Date
- 2010-06-04
- Lead Sponsor
- Hanyang University
- Target Recruit Count
- 400
- Registration Number
- NCT00886574
- Locations
- 🇰🇷
Inha University Hospital, In Cheon, Korea, Republic of
🇰🇷Hallym University Hospital, Seoul, Korea, Republic of
🇰🇷Korea University Guro Hospital, Seoul, Korea, Republic of
Cilostazol Verse Asprin for Vascular Dementia in Poststroke Patients With White Matter Lesions
- First Posted Date
- 2009-02-19
- Last Posted Date
- 2015-05-06
- Lead Sponsor
- Peking University First Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT00847860
- Locations
- 🇨🇳
Peking University First Hospital, Beijing, Beijing, China
🇨🇳Shanghai Hua Shan Hospital, Shanghai, Shanghai, China
Study of Cilostazol and Probucol to Assess Their Effects on Atherosclerosis Related Biomarker
- Conditions
- Type 2 Diabetes MellitusArteriosclerosis Obliterans
- Interventions
- First Posted Date
- 2009-01-16
- Last Posted Date
- 2010-04-22
- Lead Sponsor
- Otsuka Beijing Research Institute
- Target Recruit Count
- 200
- Registration Number
- NCT00823849
- Locations
- 🇨🇳
Peking University First Hospital, Beijing, China
Evaluation of Cilostazol in Combination With L-Carnitine
- Conditions
- Peripheral Vascular DiseaseIntermittent ClaudicationPeripheral Arterial Disease
- Interventions
- Dietary Supplement: Levocarnitine tartrateDrug: cilostazol
- First Posted Date
- 2009-01-14
- Last Posted Date
- 2019-11-29
- Lead Sponsor
- Colorado Prevention Center
- Target Recruit Count
- 164
- Registration Number
- NCT00822172
- Locations
- 🇺🇸
HPV Heart, PA, Columbia, Maryland, United States
🇺🇸University of Massachusetts Medical Center, Worcester, Massachusetts, United States
🇺🇸Radiant Research, Inc, Columbus, Ohio, United States
The Efficacy of CILostazol ON Ischemic Complications After DES Implantation
- First Posted Date
- 2008-10-21
- Last Posted Date
- 2013-12-17
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 960
- Registration Number
- NCT00776828
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.